Dyadic International (DYAI) Other financing activities (2018 - 2025)

Dyadic International (DYAI) posted Other financing activities of $4.9 million for Q4 2025, up 20174.84% sequentially from $24249.0 in Q1 2025.

Dyadic International (DYAI) Other financing activities (2018 - 2025) Analysis & Trends

Dyadic International has reported Other financing activities for 6 years, with the latest figure at $4.9 million in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (changed N/A YoY) and the FY2025 annual result came in at $4.9 million, up 20273.16% from the prior year.
Other financing activities advanced to $4.9 million in Q4 2025 per DYAI's latest filing, from $24249.0 in the prior quarter.
Over five years, Other financing activities peaked at $115.8 million in Q1 2021 and troughed at -$114.8 million in Q2 2021.
A 3-year average of $746037.3 and a median of $141500.0 in 2022 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 66071.43% in 2021, down 206070.01% in 2021.
Over 3 years, Other financing activities stood at $244500.0 in 2021, then sank by 42.13% to $141500.0 in 2022, then jumped by 3374.52% to $4.9 million in 2025.
According to Business Quant data, Other financing activities over the past three periods registered $4.9 million, $24249.0, and $141500.0 for Q4 2025, Q1 2025, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Dyadic International	19.98 Mn	19.98 Mn	-

Download Data